Deletion Mutations Keep Kinase Inhibitors in the Loop

Publication date: 11 April 2016
Source:Cancer Cell, Volume 29, Issue 4
Author(s): Daniel M. Freed, Jin H. Park, Ravi Radhakrishnan, Mark A. Lemmon
Effective clinical application of conformationally selective kinase inhibitors requires tailoring drug choice to the tumor's activating mutation(s). In this issue of Cancer Cell, Foster et al. (2016) describe how activating deletions in BRAF, EGFR, and HER2 cause primary resistance to common inhibitors, suggesting strategies for improved inhibitor selection.

Teaser

Effective clinical application of conformationally selective kinase inhibitors requires tailoring drug choice to the tumor's activating mutation(s). In this issue of Cancer Cell, Foster et al. (2016) describe how activating deletions in BRAF, EGFR, and HER2 cause primary resistance to common inhibitors, suggesting strategies for improved inhibitor selection.


from Cancer via ola Kala on Inoreader http://ift.tt/2670syp
via IFTTT